Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial

JAMA

Volumn 308, Issue 23, 2012, Pages 2497-2506

  Sullivan, David ^a   Olsson, Anders G ^b   Scott, Rob ^c   Kim, Jae B ^c   Xue, Allen ^c   Gebski, Val ^d   Wasserman, Scott M ^c   Stein, Evan A ^e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b LINKÖPING UNIVERSITY   (Sweden)

^c AMGEN INC   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 145; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCLONAL ANTIBODY; PLACEBO; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SERINE PROTEINASE; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; HIP FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE SORENESS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84871326497     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.25790     Document Type: Article

References (19)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
2. Reiner Z, Catapano AL, De Backer G, et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
3. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006; 22(11):913-927. (Pubitemid 44596492)
4. Grundy SM, Cleeman JI, Merz CN, et al National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)
5. Baigent C, Keech A, Kearney PM, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-1278.
6. Topol E. The diabetes dilemma for statin users. New York Times.March 4, 2012. http://www.nytimes.com/2012/03/05/opinion/the-diabetes-dilemmafor-statin- users.html. Accessed October 19, 2012.
7. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with highdosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19 (6):403-414. (Pubitemid 43228152)
8. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP; Ezetimibe Study Group. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57(5):363-368. (Pubitemid 36798442)
9. Ballantyne CM, Weiss R, Moccetti T, et al EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-680.
10. Benjannet S, Saavedra YG, Hamelin J, et al. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem. 2010;285(52):40965-40978.
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272.
12. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(suppl):S172-S177.
13. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on LDL-C levels: results from 2 randomized, double-blind, placebo-controlled, ascendingdose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. doi:10.1016/j.jacc.2012.08.986.
14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25): 2344-2353.
15. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36.
16. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108-1118.
17. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med. 2001;39(5):426-431. (Pubitemid 32529925)
18. Turner T, Plunkett N, Miller J, Fearn J, Stein EA. Validity of calculated LDL cholesterol by the Friedewald formula compared to LDL cholesterol measured by ultracentrifugation in patients with very low LDL [abstract A105]. American Association for Clinical Chemistry. http://www.aacc.org/events/ annualmtgdirectory/Documents/AACC-12-Abstracts-A77-A119.pdf. Accessed October 19, 2012.
19. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statinintolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142-1149.